Selenomethionine or methylseleninic acid inhibits mutagenesis of a reporter gene in mouse bone marrow

Ma Suresh Kumar, Karen Pollok, Martin L. Smith

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Recent laboratory and clinical studies have utilized selenium in the form of pure seleno-L-methionine (SeMet) in combination with DNA-damaging cancer chemotherapy drugs. In mice, the selenium protected bone marrow and other tissues from dose-limiting toxicity. In fact, because of the protection from dose-limiting toxicity, a doubling or even tripling of the maximum tolerated dose (MTD) was enabled. Previously we showed that SeMet protects bone marrow by a DNA repair mechanism that requires the XPC DNA repair protein. XPC is rate-limiting and is required for repair of cisplatin or carboplatin adducts. Herein we used a mouse strain that carries a lambda phage reporter gene in the genome that serves as a mutagenesis target. SeMet protects from carboplatin mutagenesis in mouse bone marrow. Methylseleninic acid (MSA), a metabolite of SeMet, also protected against mutagenesis in mouse bone marrow.

Original languageEnglish
Pages (from-to)291-293
Number of pages3
JournalAnticancer Research
Volume30
Issue number2
StatePublished - Feb 2010

Fingerprint

Selenomethionine
Reporter Genes
Mutagenesis
Methionine
Bone Marrow
Carboplatin
Selenium
DNA Repair
Bacteriophage lambda
Maximum Tolerated Dose
Antineoplastic Agents
Cisplatin
Genome
methylselenic acid
DNA
Proteins

Keywords

  • Carboplatin
  • Cisplatin
  • DNA repair
  • Nucleotide excision repair
  • Selenium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Selenomethionine or methylseleninic acid inhibits mutagenesis of a reporter gene in mouse bone marrow. / Kumar, Ma Suresh; Pollok, Karen; Smith, Martin L.

In: Anticancer Research, Vol. 30, No. 2, 02.2010, p. 291-293.

Research output: Contribution to journalArticle

@article{c18015c984bc4dc6a00c68dae35100db,
title = "Selenomethionine or methylseleninic acid inhibits mutagenesis of a reporter gene in mouse bone marrow",
abstract = "Recent laboratory and clinical studies have utilized selenium in the form of pure seleno-L-methionine (SeMet) in combination with DNA-damaging cancer chemotherapy drugs. In mice, the selenium protected bone marrow and other tissues from dose-limiting toxicity. In fact, because of the protection from dose-limiting toxicity, a doubling or even tripling of the maximum tolerated dose (MTD) was enabled. Previously we showed that SeMet protects bone marrow by a DNA repair mechanism that requires the XPC DNA repair protein. XPC is rate-limiting and is required for repair of cisplatin or carboplatin adducts. Herein we used a mouse strain that carries a lambda phage reporter gene in the genome that serves as a mutagenesis target. SeMet protects from carboplatin mutagenesis in mouse bone marrow. Methylseleninic acid (MSA), a metabolite of SeMet, also protected against mutagenesis in mouse bone marrow.",
keywords = "Carboplatin, Cisplatin, DNA repair, Nucleotide excision repair, Selenium",
author = "Kumar, {Ma Suresh} and Karen Pollok and Smith, {Martin L.}",
year = "2010",
month = "2",
language = "English",
volume = "30",
pages = "291--293",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Selenomethionine or methylseleninic acid inhibits mutagenesis of a reporter gene in mouse bone marrow

AU - Kumar, Ma Suresh

AU - Pollok, Karen

AU - Smith, Martin L.

PY - 2010/2

Y1 - 2010/2

N2 - Recent laboratory and clinical studies have utilized selenium in the form of pure seleno-L-methionine (SeMet) in combination with DNA-damaging cancer chemotherapy drugs. In mice, the selenium protected bone marrow and other tissues from dose-limiting toxicity. In fact, because of the protection from dose-limiting toxicity, a doubling or even tripling of the maximum tolerated dose (MTD) was enabled. Previously we showed that SeMet protects bone marrow by a DNA repair mechanism that requires the XPC DNA repair protein. XPC is rate-limiting and is required for repair of cisplatin or carboplatin adducts. Herein we used a mouse strain that carries a lambda phage reporter gene in the genome that serves as a mutagenesis target. SeMet protects from carboplatin mutagenesis in mouse bone marrow. Methylseleninic acid (MSA), a metabolite of SeMet, also protected against mutagenesis in mouse bone marrow.

AB - Recent laboratory and clinical studies have utilized selenium in the form of pure seleno-L-methionine (SeMet) in combination with DNA-damaging cancer chemotherapy drugs. In mice, the selenium protected bone marrow and other tissues from dose-limiting toxicity. In fact, because of the protection from dose-limiting toxicity, a doubling or even tripling of the maximum tolerated dose (MTD) was enabled. Previously we showed that SeMet protects bone marrow by a DNA repair mechanism that requires the XPC DNA repair protein. XPC is rate-limiting and is required for repair of cisplatin or carboplatin adducts. Herein we used a mouse strain that carries a lambda phage reporter gene in the genome that serves as a mutagenesis target. SeMet protects from carboplatin mutagenesis in mouse bone marrow. Methylseleninic acid (MSA), a metabolite of SeMet, also protected against mutagenesis in mouse bone marrow.

KW - Carboplatin

KW - Cisplatin

KW - DNA repair

KW - Nucleotide excision repair

KW - Selenium

UR - http://www.scopus.com/inward/record.url?scp=77950538388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950538388&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 291

EP - 293

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -